Analyst Jeffrey Silber from BMO Capital maintained a Buy rating on Covista and keeping the price target at $138.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jeffrey Silber has given his Buy rating due to a combination of factors that, in his view, support a constructive long-term outlook for Covista. He came away from the Investor Day more optimistic as management presented a credible strategy built on addressing healthcare workforce shortages, deepening partnerships with providers, and leveraging brand marketing alongside an emerging AI roadmap.
He also points to the company’s long-term growth targets, supported by new campus openings, expanded course offerings, and expected enrollment gains, particularly in Walden and a recovery at Chamberlain. In addition, Silber highlights Covista’s disciplined financial approach, stable regulatory and financing backdrop, and the decision to keep estimates and the price target intact, all of which reinforce his conviction that the shares remain attractive at current levels.
According to TipRanks, Silber is a 3-star analyst with an average return of 2.6% and a 48.79% success rate. Silber covers the Consumer Defensive sector, focusing on stocks such as Covista, Stride, and McGraw Hill, Inc..
In another report released today, TipRanks – Anthropic also upgraded the stock to a Buy with a $108.00 price target.